Association between antibiotic consumption and colon and rectal cancer development in older individuals: A territory-wide study

Ka Shing Cheung¹,² | Esther W. Chan³ | Anthony Tam¹ | Irene O. L. Wong⁴ | Wai Kay Seto¹,² | Ivan F. N. Hung¹ | Ian C. K. Wong³,⁵ | Wai K. Leung¹

¹Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong City, Hong Kong
²Department of Medicine, The University of Hong Kong&Shenzhen Hospital, Shenzhen, China
³Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong City, Hong Kong
⁴School of Public Health, The University of Hong Kong, Hong Kong City, Hong Kong
⁵UCL School of Pharmacy, University College London, London, UK

Correspondence
Wai K. Leung, Department of Medicine, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong City, Hong Kong. Email: waikleung@hku.hk

Abstract

Background: Antibiotics may alter colorectal cancer (CRC) risk due to gut dysbiosis. We aimed to study the specific and temporal effects of various antibiotics on CRC development in older individuals.

Methods: This was a territory-wide retrospective cohort study. Subjects aged 60 years and older who did not have CRC diagnosed on screening/diagnostic colonoscopy diagnosed between 2005 and 2013 were recruited. Exclusion criteria were history of CRC, colectomy, inflammatory bowel disease, and CRC diagnosed within 6 months of index colonoscopy. Exposure was use of any antibiotics up to 5 years before colonoscopy. The primary outcomes were CRC diagnosed > 6 mo after colonoscopy. Covariates were patient demographics, history of colonic polyps/polypectomy, concomitant medication use (NSAIDs, COX-2 inhibitors, aspirin, and statins), and performance of endoscopy centers (colonoscopy volume and polypectomy rate). Stratified analysis was conducted according to nature of antibiotics and location of cancer.

Results: Ninety seven thousand one hundred and sixty-two eligible subjects (with 1026 [1.0%] cases of CRC) were identified, 58,704 (60.4%) of whom were exposed to antibiotics before index colonoscopy. Use of antibiotics was associated with a lower risk of cancer in rectum (adjusted hazard ratio [aHR]: 0.64, 95% CI: 0.54–0.76), but a higher risk of cancer in proximal colon (aHR: 1.63, 95%CI: 1.15–2.32). These effects differed as regards the anti-anaerobic/anti-aerobic activity, narrow-/broad-spectrum, and administration route of antibiotics.

Conclusions: Antibiotics had divergent effects on CRC development in older subjects, which varied according to the location of cancer, antibiotic class, and administration route.
1 | INTRODUCTION

Globally, colorectal cancer (CRC) is currently the 3rd most common cancer, and its incidence continues to rise in many developing regions including Asia. Although various factors including westernized diets have been attributed to rapid rise of colorectal cancer incidence, disruption of gut microbiota has been increasingly linked to the development of CRC. Antibiotics are among the potent modulators of intestinal microbiota. Several proposed mechanisms include an increase in carcinogenic microbes and loss of beneficial anaerobes and weakening of host's immune defense against cancer. Intriguingly, antibiotics, in particular broad-spectrum ones, affect outcomes of cancer patients receiving immunotherapy, possibly mediated by alteration of immune response related to the intestinal microbiota.

With continuous rise in global antibiotic consumption and an estimated annual consumption of 70 billion doses, it is important to address possible association between antibiotic exposure and CRC development. However, previous studies yielded inconsistent results. The Nurses’ Health Study showed that antibiotics were associated with a higher risk of adenomas in proximal colon, but weak to no association for distal colon and rectum. While some epidemiological studies suggested increased CRC risk with prior antibiotic exposure, others did not identify such an association, and the risk was mainly limited to penicillins. Two recent studies showed that antibiotics were associated with reduced rectal cancer risk, a finding which was not reported previously. However, this study was limited to oral form of antibiotics, and did not assess effects of different antibacterial spectrum on CRC risk. None of these studies investigated the role of antibiotics in sporadic CRC development in patients without CRC detected in previous colonoscopy.

Against this background, the aim of our study was to study effects of various antibiotics (including anti-aerobic vs. anti-anaerobic, narrow- vs. broad-spectrum, and intravenous vs. oral) on development of sporadic CRC after baseline colonoscopy negative for CRC in a territory-wide cohort of older subjects.

2 | METHODS

2.1 | Data source and study design

This was a retrospective cohort study based on data retrieved from clinical data analysis and reporting system (CDARS), a territory-wide electronic database system possessed by the Hong Kong’s Hospital Authority which is the sole public healthcare provider for about 90% of all healthcare services (including primary, secondary, and tertiary) of the local 7.5 million population. The CDARS contains patient demographics and clinical data including outpatient clinic visits, hospitalization, endoscopic and surgical procedures, investigation results, and drug dispensing history. Diagnoses are recorded by the International Classification of Diseases, Ninth Revision (ICD-9) codes. Utilizing CDARS allows conduction of various large-size cohort studies with >90% accuracy of coding. We obtained ethics approval from the Institutional Review Board of the University of Hong Kong (HKU) and Hong Kong West Cluster (HKWC) of Hospital Authority. Inform consent was waived as patient confidentiality was protected by replacement of personal identity with reference key.

2.2 | Study subjects and outcome of interest

Figure S1 illustrates the patient selection process. We identified subjects aged ≥60 years who had received colonoscopy between 2005 and 2013 in all public hospitals in our locality (i.e., index date). We specifically studied this older population because of their higher CRC risk and lower possibility of hereditary syndrome (the CDARS did capture data on this aspect). Exclusion criteria were history of CRC, colectomy, inflammatory bowel disease, and detected CRC (defined as CRC diagnosed within 6 months after index colonoscopy). The primary outcome of interest was all CRC that developed >6 m after index colonoscopy. Cancer subsites were grouped into proximal (cecum, ascending, and transverse colon [ICD-9 codes: 153.4, 153.6, 153.0, 153.1]) and distal colon (splenic flexure, descending and sigmoid colon, and rectum [ICD-9 codes: 153.2, 153.3, 153.7, 154.0, 154.1]). Our previous studies showed that coding accuracy of CRC from this database was 97.1%. Patients were followed from 6 months after colonoscopy and censored at diagnosis of CRC, death, or study end date (31 December 2017).

2.3 | Exposure of interest and covariates

Exposure of interest was the use of any antibiotics before colonoscopy. Data of drug prescription and dispensing history
were retrieved up to 5 years before colonoscopy. Antibiotic use was regarded as “ever use of any antibiotics” before the index colonoscopy as in the study by Zhang et al. These included 11 classes of antibiotics, namely penicillins, cephalosporins, quinolones, tetracyclines, carbapenems, macrolides, aminoglycosides, glycopeptides, nitroimidazoles, sulf/sulfa-/trimethoprim, and other antibiotics (daptomycin, clindamycin, linezolid, nitrofurantoin, rifaximin, and rifampicin). Effects of nature of various antibiotics (anti-aerobic vs anti-anaerobic, narrow-vs. broad-spectrum, and intravenous vs. oral) on CRC development were also studied. eTable S2 shows classification of antibiotics based on anti-aerobic/anti-anaerobic effect and antibacterial spectrum.

Other covariates taken into analysis were patient characteristics and performance of endoscopy centers (polypectomy rate and endoscopy volume annually). Patient characteristics were age, sex, colonic polyp history, polypectomy at index colonoscopy, diseases related to alcoholism (gastrointestinal, hepatic, neurological, and psychiatric diseases), smoking (ICD-9 code of V15.82 and chronic obstructive pulmonary disease [COPD]), comorbidities (neurological, cardiovascular, metabolic, hepatic, and renal diseases) (Table 1) and concomitant medication use (aspirin, non-steroidal anti-inflammatory drugs, cyclooxygenase [COX]-2 inhibitors, and statins). eTable Figure S1 shows ICD-9 codes of these diseases. Other medication use was defined ≥180-day use as defined in previous study.

To investigate duration-response relationship, antibiotic use duration was categorized into three groups (1) never use, (2) < median, and (3) ≥ median.

3.4 Statistical analysis

We conducted statistical analysis by using R version 3.2.3 (R Foundation for Statistical Computing) statistical software. Continuous variables were expressed as median and interquartile range (IQR). Mann–Whitney U test was applied to compare difference in continuous variables between two groups. Chi-square test was used for categorical variables. Multivariable Cox proportional hazards model was applied to calculate the adjusted hazard ratio (aHR) of CRC with antibiotic use. Stratified analysis was conducted as regards the location of cancer (proximal and distal colon and rectum). Association between CRC and various antibiotics as well as antibiotic nature (anti-aerobic vs. anti-anaerobic, narrow-vs. broad-spectrum, and intravenous vs. oral) on CRC was also determined. Subgroup analysis was conducted as regards sex, diabetes mellitus (DM), and history of colonic polyps/polypectomy. Statistical significance is defined with a two-sided p-value of <0.05.

3 RESULTS

3.1 Characteristics of study cohort

Ninety seven thousand one hundred and sixty-two (male: 50,841 [52.3%]) subjects fulfilled the eligibility criteria (eFigure Figure S1), totaling 797,107 person-years. They underwent index colonoscopy at a median age of 71.4 years (IQR: 65.1–77.8) (Table 1).

One thousand twenty-six (1.1%) subjects were diagnosed to have CRC after colonoscopy (rectum: 601 [58.6%], proximal colon: 171 [16.7%], and distal colon: 254 [24.8%]), at an incidence rate of 2.4 per 10,000 person-years. They were diagnosed with CRC at a median age of 79.1 years (IQR: 72.9–85.0), with interval between index colonoscopy and cancer diagnosis being a median of 1.8 years (IQR:1.0–3.6).

3.2 Association between pre-colonoscopy antibiotic use and CRC

Antibiotic users had use of antibiotics for a median of 15 days (IQR:7–31). Antibiotic use before index colonoscopy was associated with a lower rectal cancer risk (aHR:0.64, 95% CI:0.54–0.76) but higher cancer risk in proximal colon (aHR:1.63, 95% CI:1.15–2.32) (Table 2). Antibiotics had no effect on the risk of cancer development in distal (aHR:0.99, 95% CI:0.76–1.30). Compared with antibiotic non-use, aHR of cancer in rectum was 0.73 (95% CI:0.59–0.91) and 0.58 (95% CI:0.48–0.71) with antibiotic use <2 weeks and ≥2 weeks, respectively (Table 3). On the contrary, aHRS of cancer in proximal colon was 1.73 (95% CI:1.15–2.60) and 1.57 (95% CI:1.07–2.30) for antibiotic use <2 weeks and ≥2 weeks, respectively.

3.3 Association between CRC and different classes of antibiotics

When compared to non-antibiotic use, penicillins were associated with a lower risk of CRC (aHR:0.83, 95% CI:0.72–0.95) and aminoglycosides were associated with a higher risk (aHR:1.53, 95% CI:1.05–2.25), while there was no significant association between CRC and other antibiotic (Table 4). Further analysis showed that the beneficial effect of penicillins was limited to rectum (aHR: 0.68, 95% CI:0.87–0.81) and the harmful effect of aminoglycosides was limited to distal colon (aHR: 2.13, 95% CI:1.21–3.77) (eTable S3).
| **Characteristics of antibiotic and nonantibiotic users** | **All (n = 97,162)** | **Antibiotic users (n = 58,704)** | **Nonantibiotic users (n = 38,458)** |
|----------------------------------------------------------|----------------------|----------------------------------|-------------------------------------|
| **Age at index colonoscopy (years)**                     | 71.4 (65.1–77.8)     | 72.7 (66.1–78.9)                 | 69.5 (64.0–75.8)                   |
| **Male sex (n, %)**                                      | 50,841 (52.3%)       | 30,625 (52.2%)                   | 20,216 (52.6%)                    |
| **History of colonic polyp (n, %)**                      | 29,663 (30.5%)       | 19,666 (27.2%)                   | 9997 (26.0%)                      |
| **Polypectomy at index colonoscopy (n, %)**              | 16,087 (16.6%)       | 10,027 (17.1%)                   | 6060 (15.8%)                      |
| **Smoking (n, %)**                                       | 3637 (3.7%)          | 3332 (5.7%)                      | 305 (0.8%)                        |
| **Alcohol (n, %)**                                       | 495 (0.5%)           | 389 (0.7%)                       | 106 (0.3%)                        |
| **DM (n, %)**                                            | 14,032 (14.4%)       | 10,533 (17.9%)                   | 3499 (9.1%)                       |
| **Hypertension (n, %)**                                  | 23,512 (24.2%)       | 17,468 (29.8%)                   | 6044 (15.7%)                      |
| **Dyslipidemia (n, %)**                                  | 7290 (7.5%)          | 5112 (8.7%)                      | 2178 (5.7%)                       |
| **AF (n, %)**                                            | 5029 (5.2%)          | 4098 (7.0%)                      | 931 (2.4%)                        |
| **IHD (n, %)**                                           | 11,141 (11.5%)       | 8394 (14.3%)                     | 2747 (7.1%)                       |
| **CHF (n, %)**                                           | 5737 (5.9%)          | 5045 (8.6%)                      | 692 (1.8%)                        |
| **Stroke (n, %)**                                        | 6541 (6.7%)          | 5066 (8.6%)                      | 1475 (3.8%)                       |
| **CRF (n, %)**                                           | 2986 (3.1%)          | 2664 (4.5%)                      | 322 (0.8%)                        |
| **Cirrhosis (n, %)**                                     | 696 (0.7%)           | 593 (1.0%)                       | 103 (0.3%)                        |
| **Dementia (n, %)**                                      | 1225 (1.3%)          | 1084 (1.8%)                      | 141 (0.4%)                        |
| **Parkinsonism (n, %)**                                  | 726 (0.7%)           | 585 (1.0%)                       | 141 (0.4%)                        |
| **Aspirin (n, %)**                                       | 22,004 (22.6%)       | 15,864 (27.0%)                   | 6140 (16.0%)                      |
| **NSAIDs (n, %)**                                        | 8000 (8.2%)          | 5649 (9.6%)                      | 2351 (6.1%)                       |
| **COX-2 inhibitors (n, %)**                              | 108 (0.1%)           | 71 (0.1%)                        | 37 (0.1%)                         |
| **Statins (n, %)**                                       | 17,651 (18.2%)       | 11,629 (19.8%)                   | 6022 (15.7%)                      |
| **Annual center endoscopy volume**                       | 2892 (2045–3316)     | 2892 (2054–3316)                 | 2887 (2033–3291)                  |
| **Annual center polypectomy rate**                       | 24.6% (21.7%–28.2%)  | 24.6% (21.7%–28.0%)              | 24.7% (21.6%–28.4%)               |

**TABLE 2** Association between colorectal cancer development and antibiotics after index colonoscopy negative for colorectal cancer

| **Number of subjects and colorectal cancer cases** | **Adjusted hazard ratio** | **95% confidence interval** | **p-value** |
|----------------------------------------------------|---------------------------|-----------------------------|-------------|
| Rectum (number = 96,737, cancer cases = 601)       |                           |                             |             |
| Antibiotic non-use                                  | Number = 38,372; Cancer = 287 | Reference                  | –           | –           |
| Any antibiotic use                                  | Number = 58,480; Cancer = 314 | 0.64                       | 0.54–0.76   | <0.001      |
| Proximal colon (Number = 96,307, Cancer cases = 171) |                           |                             |             |
| Antibiotic non-use                                  | Number = 38,080; Cancer = 45 | Reference                  | –           | –           |
| Any antibiotic use                                  | Number = 58,227; Cancer = 126 | 1.63                       | 1.15–2.32   | 0.006       |
| Distal colon (Number = 96,390, Cancer cases = 254)  |                           |                             |             |
| Antibiotic non-use                                  | Number = 38,126; Cancer = 91 | Reference                  | –           | –           |
| Any antibiotic use                                  | Number = 58,264; Cancer = 163 | 0.99                       | 0.76–1.30   | 0.965       |

*Adjusted for age, sex, colonic polyp history, polypectomy at index colonoscopy, alcohol-related diseases, smoking, other comorbidities (hypertension, dyslipidemia, diabetes mellitus, ischemic heart disease, congestive heart failure, atrial fibrillation, stroke, cirrhosis, chronic renal failure, parkinsonism, and dementia) and concurrent medications (aspirin, COX-2 inhibitors, and statins), annual center polypectomy rate, and endoscopy volume.
### 3.4 Antibiotic nature on the risk of CRC development

Analysis was limited to rectal and proximal cancer since antibiotics did not affect distal colon cancer risk. Table 5 shows the effects of different antibiotics on CRC according to (1) anti-aerobic versus anti-anaerobic activity, (2) narrow- versus broad-spectrum activity, and (3) intravenous versus oral versus both administration routes.

#### Antimicrobial nature on the risk of CRC development

Analysis was limited to rectal and proximal cancer since antibiotics did not affect distal colon cancer risk. Table 5 shows the effects of different antibiotics on CRC according to (1) anti-aerobic versus anti-anaerobic activity, (2) narrow- versus broad-spectrum activity, and (3) intravenous versus oral versus both administration routes.

**Table 3** Association between colorectal cancer and duration of antibiotic use

|                      | Number of subjects and colorectal cancer cases | Adjusted hazard ratio<sup>a</sup> | 95% confidence interval | p-value |
|----------------------|------------------------------------------------|----------------------------------|------------------------|---------|
| Rectum (number = 96,737, cancer cases = 601) |                                                |                                  |                        |         |
| Antibiotic non-use   | Number = 38,372; Cancer = 287                  | Reference                        | –                      | –       |
| <2 weeks             | Number = 21,587; Cancer = 127                  | 0.73                             | 0.59–0.91              | 0.004   |
| ≥2 weeks             | Number = 36,828; Cancer = 187                  | 0.58                             | 0.48–0.71              | <0.001  |
| Proximal colon (number = 96,307, cancer cases = 171) |                                                |                                  |                        |         |
| Antibiotic non-use   | Number = 38,080; cancer = 45                   | Reference                        | –                      | –       |
| <2 weeks             | Number = 21,509; cancer = 49                   | 1.73                             | 1.15–2.60              | 0.008   |
| ≥2 weeks             | Number = 36,718; cancer = 77                   | 1.57                             | 1.07–2.30              | 0.021   |
| Distal colon (number = 96,390, cancer cases = 254) |                                                |                                  |                        |         |
| Antibiotic non-use   | Number = 38,126; cancer = 91                   | Reference                        | –                      | –       |
| <2 weeks             | Number = 21,512; cancer = 52                   | 0.92                             | 0.65–1.30              | 0.634   |
| ≥2 weeks             | Number = 36,752; cancer = 111                  | 1.04                             | 0.78–1.40              | 0.786   |

<sup>a</sup>Adjusted for age, sex, colon polyp history, polypectomy at index colonoscopy, alcohol-related diseases, smoking, other comorbidities (hypertension, dyslipidemia, diabetes mellitus, ischemic heart disease, congestive heart failure, atrial fibrillation, stroke, cirrhosis, chronic renal failure, parkinsonism, and dementia) and concurrent medications (aspirin, COX-2 inhibitors, and statins), annual center polypectomy rate, and endoscopy volume.

**Table 4** Association between colorectal cancer development and different antibiotic classes

|                      | Adjusted hazard ratio<sup>a</sup> | 95% confidence interval | p-value |
|----------------------|-----------------------------------|------------------------|---------|
| Penicillins          | 0.83                              | 0.73–0.96              | 0.009   |
| Cephalosporins       | 0.97                              | 0.81–1.16              | 0.739   |
| Macrolides           | 1.06                              | 0.87–1.28              | 0.579   |
| Carabapenems         | 1.16                              | 0.69–1.95              | 0.574   |
| Quinolones           | 0.91                              | 0.75–1.09              | 0.297   |
| Tetracyclines        | 0.52                              | 0.25–1.10              | 0.088   |
| Aminoglycosides      | 1.53                              | 1.05–2.25              | 0.029   |
| Nitromidazoles       | 1.03                              | 0.83–1.27              | 0.818   |
| Glycopeptides        | 0.64                              | 0.31–1.31              | 0.220   |
| Sulfur and trimethoprim | 0.70                          | 0.43–1.12              | 0.548   |
| Others (clindamycin, nitrofurantoin, linezolid, rifampicin, rifaximin, daptomycin) | 0.92 | 0.70–1.20 | 0.132 |

<sup>a</sup>Adjusted for age, sex, colon polyp history, polypectomy at index colonoscopy, alcohol-related diseases, smoking, other comorbidities (hypertension, dyslipidemia, diabetes mellitus, ischemic heart disease, congestive heart failure, atrial fibrillation, stroke, cirrhosis, chronic renal failure, parkinsonism, and dementia), and concurrent medications (aspirin, COX-2 inhibitors, and statins), annual center polypectomy rate, and endoscopy volume.

### 3.4.1 Rectal cancer

Both anti-aerobic and anti-anaerobic antibiotics were associated with lower risk of cancer in rectum (aHR:0.68, 95% CI:0.49–0.93 and aHR:0.64, 95% CI:0.53–0.76, respectively). While narrow-spectrum antibiotics had no effect on rectal cancer.

(aHR:0.77, 95% CI:0.49–1.22), broad-spectrum antibiotics were associated with a lower risk of cancer in rectum...
(aHR:0.63, 95% CI:0.53–0.75). Different routes of administration yielded similar results (intravenous:0.77 [95% CI:0.50–1.18], oral:aHR 0.65 [95% CI:0.54–0.78], and both routes:0.60 [95% CI:0.47–0.76]).

3.4.2 Proximal colon cancer

While anti-aerobic antibiotics did not increase the risk of cancer in proximal colon (aHR:1.33, 95% CI:1.73–2.43), anti-anaerobic antibiotics were associated with increased risk (aHR:1.69, 95% CI:1.18–2.41). Both narrow- and broad-spectrum antibiotics were associated with raised risk of proximal colon cancer (aHR:2.08, 95% CI:1.02–4.27; and aHR:1.60, 95% CI:1.13–2.29, respectively). The aHR of intravenous and oral antibiotics was 2.61 (95% CI:1.37–4.97) and 1.53 (95% CI:1.05–2.24), respectively.

### Table 5 Association between nature of antibiotics and CRC as regards anatomical location

| Number of subjects and colorectal cancer cases | Adjusted hazard ratio | 95% confidence interval | p-value |
|-----------------------------------------------|-----------------------|------------------------|---------|
| Rectum (Number = 96,737, Cancer = 601)        |                       |                        |         |
| Anti-aerobic vs anti-anaerobic activity       |                       |                        |         |
| Antibiotic non-use Number = 38,322; Cancer = 287 | Reference            | –                      | –       |
| Anti-aerobic Number = 8034; Cancer = 43       | 0.68                  | 0.49–0.93              | 0.017   |
| Anti-anaerobic Number = 50,381; Cancer = 271 | 0.64                  | 0.53–0.76              | <0.001  |
| Narrow- vs broad-spectrum activity            |                       |                        |         |
| Antibiotic non-use Number = 38,322; Cancer = 287 | Reference            | –                      | –       |
| Narrow-spectrum Number = 3543; Cancer = 20    | 0.77                  | 0.49–1.22              | 0.277   |
| Broad-spectrum Number = 54,872; Cancer = 294 | 0.63                  | 0.53–0.75              | <0.001  |
| Intravenous vs oral antibiotics               |                       |                        |         |
| Antibiotic non-use Number = 38,322; Cancer = 287 | Reference            | –                      | –       |
| Intravenous Number = 3481; Cancer = 23       | 0.77                  | 0.50–1.18              | 0.237   |
| Oral Number = 34,690; Cancer = 178           | 0.65                  | 0.54–0.78              | <0.001  |
| Both (intravenous and oral) Number = 20,244; Cancer = 113 | 0.60 | 0.47–0.76 | <0.001 |
| Proximal colon (n = 96,307, Cancer = 171)    |                       |                        |         |
| Anti-aerobic vs. anti-anaerobic activity      |                       |                        |         |
| Antibiotic non-use Number = 38,080; Cancer = 45 | Reference            | –                      | –       |
| Anti-aerobic Number = 8005; Cancer = 14       | 1.33                  | 0.73–2.43              | 0.354   |
| Anti-anaerobic Number = 50,222; Cancer = 112 | 1.69                  | 1.18–2.41              | 0.004   |
| Narrow- vs. broad-spectrum activity           |                       |                        |         |
| Antibiotic non-use Number = 38,080; Cancer = 45 | Reference            | –                      | –       |
| Narrow-spectrum Number = 3532; Cancer = 9     | 2.08                  | 1.02–4.27              | 0.045   |
| Broad-spectrum Number = 54,695; Cancer = 117 | 1.60                  | 1.13–2.29              | 0.009   |
| Intravenous vs oral antibiotics               |                       |                        |         |
| Antibiotic non-use Number = 38,080; Cancer = 45 | Reference            | –                      | –       |
| Intravenous Number = 3470; Cancer = 12       | 2.61                  | 1.37–4.97              | 0.004   |
| Oral Number = 34,580; Cancer = 68             | 1.53                  | 1.05–2.24              | 0.028   |
| Both (intravenous and oral) Number = 20,177; Cancer = 46 | 1.65 | 1.07–2.56 | 0.024 |

*aAdjusted for age at which index colonoscopy was performed, sex, history of colonic polyps, polypectomy at index colonoscopy, alcohol consumption, smoking, other comorbidities (hypertension, dyslipidemia, diabetes mellitus, ischemic heart disease, congestive heart failure, atrial fibrillation, stroke, cirrhosis, chronic renal failure, parkinsonism, and dementia) and concurrent medications (aspirin, COX-2 inhibitors, and statins), annual center endoscopy volume, and center polypectomy rate.

3.5 Subgroup analysis of antibiotics on CRC

eTable S4 shows that the protective effects of antibiotics on rectal cancer persisted in different subgroups with similar effect magnitudes even after stratification according to patient’s sex, history of DM, and colonic polyps. For proximal colon cancer, the harmful effects of antibiotics were limited to males (aHR:2.28, 95% CI:1.34–3.88),
nondiabetic patients (aHR:1.67, 95% CI: 1.17–2.43), and patients with colonic polyp history (aHR:1.85, 95% CI: 1.12–3.04).

4 | DISCUSSION

This is the first comprehensive study, which involved >90,000 older subjects, to demonstrate the differential effects of pre-colonoscopy antibiotics use on subsequent sporadic CRC risk according to cancer location after negative baseline colonoscopy. We found that antibiotics had divergent effects on cancer development in rectum (36% lower risk) and proximal colon (63% higher risk), but relatively neutral effect in distal colon. The associations also varied with different classes or spectrum of antibiotics, with penicillins and aminoglycosides being associated with lower and higher CRC risk, respectively. Further analysis showed that both anti-anaerobic and anti-aerobic antibiotics were associated with lower rectal cancer risk, but only anti-anaerobic antibiotics were associated with higher proximal cancer risk.

Antibiotics exert differential effects on proximal and distal cancer development was only recently reported in an epidemiological study from the United Kingdom.14 In their case–control study, antibiotics were associated with higher proximal colon cancer risk, particularly with anti-anaerobic antibiotics, but lower risk in rectum. As yet, our study was different from Zhang’s study by including older patients only who were more likely to have sporadic CRC. Moreover, our cohort design included all patients who had baseline colonoscopies that were negative for cancer rather than case–control design. Third, we accounted for antibiotics that were given by intravenous route and not limited to oral antibiotics only. Lastly, CRCs were predominantly rectal cancer (58.6%) in our study when compared to the UK study (rectal cancer 31.9%). Despite the difference in study design, patient’s ethnic origin, and even cancer characteristics, both studies demonstrated similar divergent effects of antibiotics regarding the risks of cancer in proximal colon and rectum.

The reasons behind the differential effects of antibiotics on CRC remains perplexing. Gut dysbiosis induced by antibiotics has been linked with CRC development due to a possible increase in pro-neoplastic microbiota and loss of health-promoting anaerobes.3,4 For instance, increase in abundance of colibactin-producing *Escherichia coli*, *Fusobacterium nucleatum*, and enterotoxigenic *Bacteroides fragilis* in CRC, with depletion of butyrate-producing microbes are reported in CRC.30,31 Animal models also showed that antibiotics could affect the metabolome-related carcinogenesis pathway,32 including reduction in short-chain fatty acids levels from microbial fermentation which would disrupt cell proliferation/apoptosis, regulation of inflammation, and immune response. Bacterial translocation from antibiotic also could increase intestinal permeability and activate immune system with ensuing chronic inflammation.33 However, it remains unknown to show effects of antibiotics on CRC development could be as topical as shown in the current study. The proximal colon is the first site of exposure to incompletely absorbed antibiotics, and the impact of antibiotics on polymicrobial invasive biofilms may therefore be more prominent in the proximal colon.34,35 The different distribution of various microbes along the colorectum continuum is another possible reason accounting for the divergent outcomes. A previous study showed that the density gradient of *F. nucleatum* decreased from proximal colon to rectum.36 It has also been shown that the bacterial activity of *Bacteroidetes*, *Firmicutes*, and *Actinobacteria* (which produce health-promoting products like acetate, propionate, and butyrate) are the highest in proximal colon, and fermentation of bacterial proteins and amino acids into toxic metabolites (e.g., branched-chain fatty acids) take place in distal colon.37 It has been postulated that host factors involved in immune and microbial homeostasis reduce caudally, hence favoring proliferation of pro-neoplastic microbes to increase the susceptibility of the distal colorectum to injury. This notion is illustrated by a recent study that dietary pattern that promote sulfur-metabolizing microbes increased cancer risk in distal colorectum but not proximal colon.38 In addition, difference in embryonic origin of distal and proximal colon could partly explain different molecular and clinicopathological characteristics of CRCs, and hence antibiotic effects.39

In this study, longer duration (>2 weeks) of antibiotic use associated with even lower risk of rectal cancer, and similar duration effects of antibiotics were not observed in proximal cancer. It remains uncertain whether proximal colon is more susceptible to antibiotics than the rectum, and hence even 2 weeks may be sufficient to cause disruption of proximal colon microbiota. This is consistent with the study findings by Zhang et al.14 which reported that proximal colon cancer risk increased after minimal antibiotic use (less than 2 weeks) and reached a plateau after 60 days of cumulative exposure (p-nonlinear = 0.0179). Although gut microbiota and metabolites may be affected even by short-term antibiotic usage, false-negative colonoscopy (in particular proximal colon), and ascertainment/detection bias may bias the result. False-negative colonoscopy was a concern as the majority of our patients develop CRC within 4 years after negative baseline colonoscopy. Ascertainment/detection bias in which antibiotic users were less healthy with more frequent colonoscopy may result in earlier cancer diagnosis.
In our study, different effects on CRC were observed in antibiotics with different antibacterial spectrum and route of administration. Notably, while both anti-aerobic and anti-anaerobic antibiotics were associated with lower rectal cancer, there was statistical significance for broad-spectrum and oral antibiotics only. In contrast, while there was a higher risk of proximal colon cancer regardless of antibiotic spectrum or route, statistical significance was present for anti-anaerobic antibiotics only. Nevertheless, numerically the direction of effect appears to be consistent as regards the antibiotics nature and route, and underpower was a possibility due to subgroup analysis.

Our subgroup analysis also shows that protective effects of antibiotics on rectal cancer did not differ with patient's sex, presence of DM, or history of colonic polyps. On the other hand, harmful effects of antibiotics in proximal colon cancer were limited to males, nondiabetic patients, and subjects with colonic polyp history.

The inhibition of colibactin-producing bacteria\(^{30,31}\) may explain a protective effect of penicillins, in particular proximal colon. Aminoglycosides were found to be associated with higher risk of colon cancer, in particular distal colon, which may be related to lower levels of short-chain fatty acids from microbial fermentation.\(^{32}\) Further studies are necessary to identify the underlying mechanisms of these discrepancies.

A number of strengths existed for this study. First, our territory-wide database enables the comprehensive capture of diagnoses and drug history, minimizing biases inherent to observational studies such as recall and selection biases.\(^{25}\) Reverse causality was largely avoided as there was a minimum of 6-month lapse between last antibiotic use and CRC development due to exclusion of cancer ≤6 m after index colonoscopy. Immortal time bias also did not exist as antibiotic exposure was defined before index colonoscopy.

Our study had a few limitations. First, some data of CRC risk factors such as lifestyle factors and family history were not available. Nevertheless, given the similar proportion of patients with history of colonic polyps and polypectomy between antibiotic users and non-users, a significant difference was unlikely. Moreover, we included older subjects who were less likely to suffer from hereditary cancer. Use of diagnosis codes to identify smoking and alcoholism could also underestimate their true prevalence. Second, quality metrics of index colonoscopy (e.g., quality of bowel preparation, adenoma detection rate of endoscopists) were not recorded in the database. To overcome this, we used polypectomy rates and colonoscopy volume of endoscopy centers as surrogate markers of center’s performances for adjustment in multivariable analysis. Third, mechanisms and reasons of the CRC could not be ascertained, precluding further investigation into how antibiotics modify early CRC development after index colonoscopy. Notably, false-negative colonoscopy and ascertainment/detection bias may affect the study results. However, divergent effects of antibiotics as regards different colonic segments and nature of antibiotics makes this concern less substantiated. In addition, adjustment for an extensive set of comorbidities minimized this possible bias.

5 | CONCLUSION

In this study of >90,000 subjects with baseline colonoscopy negative for CRC, a lower risk of cancer in rectum but higher risk in proximal colon was observed with antibiotic use. This observation differed as regards the class and spectrum of antibiotics. Future studies should focus on the interaction between antibiotics and gut microbiota on the development of CRC.

CONFLICT OF INTEREST

EWC has received funding from Bayer, Bristol-Myers Squibb, Pfizer, and Takeda, for work unrelated to this study. WKS has received speaker fees from AbbVie, Eisai, Mylan, and Gilead Sciences, honorarium for attending advisory board for AbbVie, Celltrion, CSL Behring, and Gilead Sciences, and received research funding from Echosens and Gilead Sciences but not related to the current study.

ICKW has received grants from Janssen, Pfizer, Bayer, Amgen, and Novartis but not related with the present study. WKL has received speaker fee from Eisai, Ipsen, and honorarium for attending advisory board for Janssen and Pfizer.

AUTHOR CONTRIBUTION

Dr. Ka Shing Cheung was involved with study concept and design; analysis and interpretation of data; drafting of manuscript; and approval of the final version of the manuscript. Dr. Esther W Chan, Ms Lijia Chen, Dr. Anthony Tam, and Dr. Wai Kay Seto were involved with acquisition of data; critical revision of the manuscript for important intellectual content; and approval of the final version of the manuscript. Dr. Irene OL Wong was involved in critical revision of the manuscript for important intellectual content; Professors Ian CK Wong and Wai K Leung were involved with the study concept and design; analysis and interpretation of data; drafting of manuscript; critical revision of the manuscript for important intellectual content; study supervision; and approval of the final version of the manuscript.
ETHICS STATEMENT
We obtained ethics approval from the Institutional Review Board of the University of Hong Kong (HKU) and Hong Kong West Cluster (HKWC) of Hospital Authority. Inform consent was waived as patient confidentiality was protected by replacement of personal identity with reference key.

DATA AVAILABILITY STATEMENT
Our study retrieved data from electronic healthcare database and id not include patients as study participants. We will disseminate the results via general media, but not directly to patients.

ORCID
Irene O. L. Wong® https://orcid.org/0000-0003-4765-9913
Wai K. Leung® https://orcid.org/0000-0002-5993-1059

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
2. Li J, Zhang AH, Wu FF, Wang XJ. Alterations in the gut microbiota and their metabolites in colorectal cancer: recent Progress and future prospects. Front Oncol. 2022;12:841552.
3. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis. 2001;1:101-104.
4. Lofmark S, Jernberg C, Jansson JK, Edlund C. Clindamycin-use predicts subsequent risk of colorectal cancer: a Swedish Nationwide population-based study. J Natl Cancer Inst. 2022;114:38-46.
5. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis. 2001;1:101-104.
6. Elkrief A, Derosa L, Kroemer G, Zitvogel L, Routy B. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? Ann Oncol. 2019;30:1572-1579.
7. Pinato DJ, Howlett S, Ottaviani D, et al. Association of Prior Antibiotic Treatment with Survival and Response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019;5:1160-1167.
8. van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14:742-750.
9. Cao Y, Wu K, Mehta R, et al. Long-term use of antibiotics and risk of colorectal adenoma. Gut. 2018;67:672-678.
10. Kilkkinen A, Rissanen H, Klaucka T, et al. Antibiotic use predicts an increased risk of cancer. Int J Cancer. 2008;123:2152-2155.
11. Dick VK, van Oijen MG, Smets HM, et al. Frequent use of antibiotics is associated with colorectal cancer risk: results of a nested case-control study. Dig Dis Sci. 2016;61:255-264.
12. Bouris B, Haynes K, Mamtani R, Yang YX. Impact of antibiotic exposure on the risk of colorectal cancer. Pharmacoepidemiol Drug Saf. 2015;24:534-542.
to colorectal cancer: a postcolonoscopy study in 187 897 patients. Gut. 2019;68:1979-1985.
29. Boudreau DM, Koehler E, Rulyak SJ, Haneuse S, Harrison R, Mandelson MT. Cardiovascular medication use and risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:3076-3080.
30. Song M, Chan AT. Environmental factors, gut microbiota, and colorectal cancer prevention. Clin Gastroenterol Hepatol. 2019;17:275-289.
31. Tilg H, Adolph TE, Gerner RR, Moschen AR. The intestinal microbiota in colorectal cancer. Cancer Cell. 2018;33:954-964.
32. Willing BP, Russell SL, Finlay BB. Shifting the balance: antibiotic effects on host-microbiota mutualism. Nat Rev Microbiol. 2011;9:233-243.
33. Tulstrup MV, Christensen EG, Carvalho V, et al. Antibiotic treatment affects intestinal permeability and gut microbial composition in Wistar rats dependent on antibiotic class. PLoS One. 2015;10:e0144854.
34. Dejea CM, Wick EC, Hechenbleikner EM, et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci U S A. 2014;111:18321-18326.
35. Tomkovich S, Dejea CM, Winglee K, et al. Human colon mucosal biofilms from healthy or colon cancer hosts are carcinogenic. J Clin Invest. 2019;130:1699-1712.
36. Mima K, Cao Y, Chan AT, et al. Fusobacterium nucleatum in colorectal carcinoma tissue according to tumor location. Clin Transl Gastroenterol. 2016;7:e200.
37. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DI, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013;54:2325-2340.
38. Nguyen LH, Ma W, Wang DD, et al. Association between sulfur-metabolizing bacterial communities in stool and risk of distal colorectal cancer in men. Gastroenterology. 2020;158:1313-1325.
39. Yasumaru M, Tsuji S, Tsujii M, et al. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway. Cancer Res. 2003;63:6726-6734.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** Cheung KS, Chan EW, Tam A, et al. Association between antibiotic consumption and colon and rectal cancer development in older individuals: A territory-wide study. Cancer Med. 2022;00:1-10. doi: 10.1002/cam4.4759